Biomarkers in Medicine is a prominent academic journal dedicated to advancing the field of medical biochemistry and drug discovery. Published by Future Medicine Ltd in the United Kingdom, this journal aims to provide a platform for researchers, clinicians, and biotechnology professionals to share their findings on the critical role of biomarkers in diagnosis, treatment, and prognosis of various diseases. With a focus on high-quality, peer-reviewed research, Biomarkers in Medicine supports the dissemination of innovative approaches and therapeutic developments across its converged publication years from 2008 to 2024. Rated in the Q3 category for biochemistry (medical), clinical biochemistry, and drug discovery, it occupies a significant place in its field, attracting contributions that push the boundaries of knowledge and application. Although it does not offer open access, the journal remains committed to excellence and rigor in the representation of ground-breaking studies, making it an essential resource for scholars and professionals eager to stay at the forefront of biomarker research.

Proteome Science is an esteemed academic journal specializing in the field of proteomics, providing a platform for advanced research and discussions surrounding the structure, function, and dynamics of proteins in biological systems. Published by BMC, a reputable publisher recognized for its commitment to open-access publishing, Proteome Science has been disseminating pivotal research findings since its inception in 2003. Targeted towards researchers, professionals, and students in biochemistry and molecular biology, the journal aims to foster collaboration and innovation within the scientific community. While it currently holds a Q3 quartile ranking in both Biochemistry and Molecular Biology categories, its impactful contributions to the field are reflected in its accessibility, as evidenced by its open access policy. By embracing collaborative research methodologies and providing a platform for novel findings, Proteome Science plays a crucial role in advancing the understanding of proteomic analyses, catering to a global audience that values groundbreaking scientific discovery.

Molecular Omics is a premier, peer-reviewed journal published by the Royal Society of Chemistry, focusing on the interdisciplinary field of molecular biology with significant implications for biochemistry and genetics. With an E-ISSN of 2515-4184, this journal has been dedicated to disseminating high-quality research since its inception in 2018, maintaining an impressive trajectory in academic contributions until 2024. Currently, it holds a Q2 quartile ranking in both Biochemistry and Genetics, alongside a Q3 ranking in Molecular Biology for 2023, highlighting its relevance and influence in these domains. The journal is accessible as an open access publication, promoting the widespread dissemination of groundbreaking research. As part of a vibrant academic community, Molecular Omics aims to bridge fundamental and applied science, appealing to researchers, professionals, and students eager to expand their knowledge on molecular mechanisms and technologies that shape the future of biological research.

Metabolomics is a distinguished academic journal published by SPRINGER, dedicated to advancing the field of metabolomics and its applications in various biochemistry-related domains. With a focus on innovative research in biochemistry, clinical biochemistry, and endocrinology, diabetes, and metabolism, this journal holds a significant position, being categorized in the Q2 quartile across multiple fields in the 2023 rankings. The journal is indexed with notable metrics: ranking 73rd in Endocrinology, Diabetes and Metabolism and 38th in Clinical Biochemistry on Scopus, demonstrating its impactful contribution to the scientific community. Established in 2005, Metabolomics provides a vital platform for researchers, professionals, and students to access high-quality research, facilitating advancements in our understanding of metabolic processes and their implications in health and disease. Access options include subscription-based reading, ensuring that valuable insights are available to a broad audience across the globe.

Biomarker Insights, published by SAGE Publications Ltd, is a leading open-access journal dedicated to advancing the field of biomarker research and its applications in health and disease. With an ISSN of 1177-2719 and an E-ISSN of 1177-2719, this journal has been at the forefront of disseminating high-quality scientific findings since its inception in 2006. Based in New Zealand, it has achieved a notable impact within the academic community, ranking in Q2 for Biochemistry (medical) and Molecular Medicine, and Q1 in Pharmacology as of 2023. This positions Biomarker Insights as a critical resource for researchers, professionals, and students alike, looking to explore innovative methodologies and applications in biomarker discovery and validation. With a commitment to open access, the journal ensures that groundbreaking research is readily available to the global community, fostering collaboration and innovation in the ever-evolving field of biomedical sciences.

Proteomes, published by MDPI since 2013, is a notable open access journal that occupies a critical place in the realms of Biochemistry, Clinical Biochemistry, Molecular Biology, and Structural Biology. Based in Switzerland, this journal not only promotes the dissemination of high-quality research pertaining to protein structures and functions but also emphasizes interdisciplinary approaches that bridge various fields of biomedical science. With a Category Quartile ranking of Q2 across multiple pertinent categories in 2023, Proteomes boasts a competitive impact within the scientific community, evidenced by its robust Scopus rankings. Researchers, professionals, and students are invited to explore a wealth of pioneering studies and reviews that are made freely accessible, aligning with global trends in open scientific communication. Whether contributing original research or seeking to expand their knowledge, the journal serves as an invaluable resource for anyone engaged in the evolving landscape of proteomics.

Translational Cancer Research, published by AME Publishing Company in Hong Kong, is a pivotal journal aimed at fostering the advancement of oncology-related knowledge through the dissemination of high-quality research findings. With its ISSN 2218-676X and E-ISSN 2219-6803, this journal serves as a vital resource for researchers, professionals, and students in the fields of Cancer Research, Oncology, and Radiology, Nuclear Medicine, and Imaging. Established in 2012, the journal covers the latest breakthroughs and cross-disciplinary approaches that drive innovation in cancer treatment and diagnostics. Although currently classified in the Q4 Quartile for Cancer Research and Q3 for both Oncology and Radiology, Translational Cancer Research continuously works toward improving its academic influence and impact, evidenced by its ongoing research contributions. The journal emphasizes open access, making crucial research available to a global audience. We invite scholars and industry professionals to engage with the latest findings and discussions within these critical areas of medical science.

AMYLOID - JOURNAL OF PROTEIN FOLDING DISORDERS, published by Taylor & Francis Ltd, is a premier academic journal dedicated to the crucial field of protein folding disorders, offering a vital platform for researchers and healthcare professionals. With an impressive impact factor and classified in the Q1 quartile across both Internal Medicine and Miscellaneous Medicine categories, this journal ranks within the top 15% of its field according to Scopus, with a remarkable rank of #18 out of 167. Covering interdisciplinary approaches that intersect molecular biology, neuroscience, and clinical implications of amyloidosis and related disorders, AMYLOID encourages the dissemination of innovative research findings from 1994 to 2024 and beyond. Despite lacking Open Access options, the journal remains a significant resource for advancing the understanding of protein misfolding diseases, influencing clinical practice and therapeutic developments. With its longstanding commitment to high-quality research, AMYLOID continues to be an essential reading for scholars, practitioners, and students who aim to make significant contributions to this evolving field.

MASS SPECTROMETRY REVIEWS, published by Wiley, is a premier academic journal dedicated to advancing the field of mass spectrometry and its applications across a multitude of scientific disciplines. With an ISSN of 0277-7037 and an E-ISSN of 1098-2787, the journal has established itself as a vital resource within the realms of Analytical Chemistry, Biochemistry, Genetics, Condensed Matter Physics, and Spectroscopy, achieving Q1 status across these categories in 2023. As a testament to its significant contribution to scholarly research, it boasts impressive Scopus rankings, including a rank of #2 out of 76 in Chemistry - Spectroscopy and #4 out of 156 in Chemistry - Analytical Chemistry, placing it in the 97th percentile and above. Emphasizing high-quality, peer-reviewed research, MASS SPECTROMETRY REVIEWS serves as an essential platform for researchers, professionals, and students aiming to stay abreast of cutting-edge developments and methodologies in mass spectrometry. The journal is committed to fostering a deeper understanding of mass spectrometric techniques while also contributing to interdisciplinary advancements, making it a valuable addition to any academic library. Authors seeking to disseminate their work in a journal with a strong reputation and impact in the scientific community will find MASS SPECTROMETRY REVIEWS an ideal venue.

PROTEOMICS is a leading journal focused on the rapidly evolving field of proteomics, published by WILEY in Germany. With a solid reputation established since its inception in 2001, it has continually contributed to the understanding of protein functions and interactions within biological systems. As part of its commitment to academic excellence, PROTEOMICS is ranked in the second quartile for both Biochemistry and Molecular Biology categories (2023), reflecting its significant influence in advancing research in these areas. Although it does not currently provide open access options, it remains a vital resource for researchers, professionals, and students keen to explore innovative methodologies and findings in proteomic research. By publishing groundbreaking studies that bridge theoretical knowledge with practical applications, PROTEOMICS plays a crucial role in enhancing our understanding of molecular processes and driving forward advancements in the life sciences.